Merck, Moderna Melanoma Vaccine Study Succeeds
Merck and Moderna announced positive results from a large late-stage trial of their personalized mRNA cancer vaccine, which significantly reduced the recurrence of melanoma, the deadliest form of skin cancer.
Madison Muller reports on "Bloomberg Open Interest." (Source: Bloomberg)
Merck, Moderna melanoma vaccine succeeds
- Merck, Moderna claim 'promising' skin cancer vaccine results in key trial IOL —
- Merck, Moderna claim encouraging melanoma vaccine trial results South China Morning Post —
- Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning The New York Times —
- Merck, Moderna Stocks Soar After Melanoma Trial Success 📹 Bloomberg — · 2min
- Moderna Cancer Trial Success Is a Shot in the Arm for Trump Newsweek —